Novo Nordisk's potential layoffs come as the pharmaceutical major, which has developed the weight-loss drug Wegovy, seeks to reduce costs amid a fierce battle with Eli Lilly for the weight-loss drug ...

Novo Nordisk NOVO.B2.49%increase; green up pointing triangle said it would take over a drug under development to treat rare blood and kidney disorders from Nasdaq-listed biopharmaceutical firm Omeros ...

It appears problems at Novo Nordisk’s recently acquired manufacturing facility in Indiana aren’t going to be solved any time soon. The FDA has tagged the former Catalent facility with an official ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. A troubled Indiana ...

Novo Nordisk is drawing divided views from Wall Street analysts. Some may be disappointed by the loss of market share to Eli Lilly. Three events could turn sentiment positive in the coming months. The ...

(Reuters) -Novo Nordisk has decided to discontinue its cell therapy research and development efforts, a spokesperson for the Danish drugmaker told Reuters on Friday. Bloomberg News first reported on ...

Novo Nordisk A/S agreed to buy Akero Therapeutics Inc. for as much as $5.2 billion to expand its portfolio in a type of liver disease that’s linked to obesity. Novo will pay $54 a share in cash, ...

Novo Nordisk A/S (NYSE:NVO) is down 1% to trade at $59 this morning, after news surfaced that the pharmaceutical concern has entered an agreement to purchase U.S.-based peer Akero Therapeutics Inc ...

Novo Nordisk may be breaking Heartseed's heart. As part of a company-wide restructuring under new CEO Maziar Mike Doustdar, the big pharma has axed a cell therapy collaboration with Heartseed worth ...

Morgan Stanley analysts say a trial to test whether Novo Nordisk’s blockbuster weight-loss drug also will work against Alzheimer’s is likely to fail, as it set the most pessimistic target price ...

Because of its size, the drugmaker has an outsize effect on the country. Now, as it sheds jobs, forecasts for Denmark’s growth are falling, too. By Eshe Nelson The success of Novo Nordisk, the ...

London's Financial Times highlights improved weight loss from taking more Ozempic. Eli Lilly's Mounjaro still seems more effective. Novo Nordisk stock is responding positively to the news, up 2.1% ...